子宮頸癌診断検査の世界市場2019-2023

◆英語タイトル:Global Cervical Cancer Diagnostic Testing Market 2019-2023
◆商品コード:IRTNTR30216
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年11月21日
◆ページ数:118
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥374,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD5,000 ⇒換算¥535,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

世界的な高齢者人口の増加に伴い、加齢は子宮頸癌の進行に関して予後の役割を担っています。米国国勢調査局によると、世界の高齢者人口(65歳以上)は2050年までに15億人を超えると予測され、世界人口の約16%となります。
疾病管理予防センター(CDC)によると、2015年には米国だけでも60から64歳の女性のうち、1,171例の子宮頸がんが見つかりました。
早期発見が不十分であるため、65歳以上の高齢の女性の中には、診断時にステージが進んでしまっているために死亡する可能性がより高くなっています。
適切な意識啓発プログラムがあれば、この病気に関する誤解を減らすことができます。その結果、健診がもっと取り入れられたり、診断キットが使用されることにつながります。
Technavioのアナリストは、子宮頸癌診断検査の世界市場が2023年までに6%以上のCAGRで成長すると予測しています。

主な分析対象企業は、Abbott Laboratories、BD、F. Hoffmann-La Roche、Hologic、QIAGENなどです。

当調査レポートでは、子宮頸癌診断検査の世界市場について調査・分析し、市場概要、市場環境、子宮頸癌診断検査市場規模、エンドユーザー別分析、種類別(Papスメア検査、HPV検査)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。

・エグゼクティブサマリー
・調査範囲・調査手法
・子宮頸癌診断検査の世界市場概要
・子宮頸癌診断検査の世界市場環境
・子宮頸癌診断検査の世界市場動向
・子宮頸癌診断検査の世界市場規模
・子宮頸癌診断検査の世界市場:業界構造分析
・子宮頸癌診断検査の世界市場:エンドユーザー別
・子宮頸癌診断検査の世界市場:種類別(Papスメア検査、HPV検査)
・子宮頸癌診断検査の世界市場:地域別市場規模・分析
・子宮頸癌診断検査の北米市場規模・予測
・子宮頸癌診断検査のヨーロッパ・中東・アフリカ市場規模・予測
・子宮頸癌診断検査のアジア太平洋市場規模・予測
・子宮頸癌診断検査の主要国分析
・子宮頸癌診断検査の世界市場:意思決定フレームワーク
・子宮頸癌診断検査の世界市場:成長要因、課題
・子宮頸癌診断検査の世界市場:競争環境
・子宮頸癌診断検査の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

117 pages, November 2018
About this market
With the growth in geriatric population worldwide, the increasing age plays a significant prognostic role in the development of cervical cancer. According to the US Census Bureau, the global geriatric population (65 years and above) is expected to exceed 1.5 billion by 2050, making it approximately 16% of the total world’s population. For instance, according to the CDC, in 2015, there were 1,171 cases of cervical cancer among women aged 60-64 years in the US alone. Due to the lack of early detection, several elderly women aged 65 years and above are more likely to die due to their advanced stage at diagnosis. Nevertheless, with adequate awareness and education programs, the misperception about the disease can be reduced. This will result in the higher adoption of screening, thereby leading to the increased use of diagnostic kits. Technavio’s analysts have predicted that the cervical cancer diagnostic testing market will register a CAGR of more than 6% by 2023.
Market Overview
Increased adoption of HPV home testing kits
Several large companies are focused on R&D of new and innovative products that can provide accurate and instant test results at home and cut down cost burden on the patients on management of cervical cancer. In addition, the rising awareness on the importance of cervical cancer screen on time will fuel the demand for cervical cancer diagnostic market during the next five years.
Varying screening policies
The recommended screening policies for cervical cancer usually vary in different countries. Although certain professional societies and organizations have developed guidelines, efforts are needed for their uniform implementation. The difference in the target age can lead to shortcomings in terms of routine registration for the screening program, evaluation, and monitoring, which can negatively impact the adoption of cervical cancer diagnostic testing.
For the detailed list of factors that will drive and challenge the growth of the cervical cancer diagnostic testing market during the 2019-2023 period, view our report.
Competitive Landscape
The market appears to be quite fragmented but will become highly concentrated with the presence of a few companies including Abbott Laboratories and BD, the competitive environment is very intense. Factors such as the growth in geriatric population and increased adoption of HPV home testing kits, will provide considerable growth opportunities to cervical cancer diagnostic testing vendors. Abbott Laboratories, BD, F. Hoffmann-La Roche, Hologic, and QIAGEN are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY END-USER
PART 07: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Pap smear test – Market size and forecast 2018-2023
• HPV testing – Market size and forecast 2018-2023
• Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TECHNOLOGY
PART 10: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 11: MARKET SEGMENTATION BY METHOD
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 14: MARKET TRENDS
PART 15: VENDOR LANDSCAPE
• Overview
• Landscape disruption
PART 16: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Abbott Laboratories
• BD
• F. Hoffmann-La Roche
• Hologic
• QIAGEN
PART 17: APPENDIX
Research methodology
List of abbreviations
PART 18: EXPLORE TECHNAVIO

Exhibit 01: Global molecular diagnostics market
Exhibit 02: Segments of global molecular diagnostics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition – Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition – Five forces 2018
Exhibit 17: End-user – Market share 2018-2023 (%)
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Pap smear test – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Pap smear test – Year-over-year growth 2019-2023 (%)
Exhibit 22: HPV testing – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: HPV testing – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 30: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 32: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Method- Market share 2018-2023 (%)
Exhibit 37: Impact of drivers and challenges
Exhibit 38: Growing percentage of elderly women population 2010-2016
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Abbott Laboratories – Vendor overview
Exhibit 45: Abbott Laboratories – Business segments
Exhibit 46: Abbott Laboratories – Organizational developments
Exhibit 47: Abbott – Geographic focus
Exhibit 48: Abbott Laboratories – Segment focus
Exhibit 49: Abbott Laboratories – Key offerings
Exhibit 50: BD – Vendor overview
Exhibit 51: BD – Business segments
Exhibit 52: BD – Organizational developments
Exhibit 53: BD – Geographic focus
Exhibit 54: BD – Segment focus
Exhibit 55: BD – Key offerings
Exhibit 56: F. Hoffmann-La Roche – Vendor overview
Exhibit 57: F. Hoffmann-La Roche – Business segments
Exhibit 58: F. Hoffmann-La Roche – Organizational developments
Exhibit 59: F. Hoffmann-La Roche – Geographic focus
Exhibit 60: F. Hoffmann-La Roche – Segment focus
Exhibit 61: F. Hoffmann-La Roche – Key offerings
Exhibit 62: Hologic – Vendor overview
Exhibit 63: Hologic – Business segments
Exhibit 64: Hologic – Organizational developments
Exhibit 65: Hologic – Geographic focus
Exhibit 66: Hologic – Segment focus
Exhibit 67: Hologic – Key offerings
Exhibit 68: QIAGEN – Vendor overview
Exhibit 69: QIAGEN – Business segments
Exhibit 70: QIAGEN – Organizational developments
Exhibit 71: QIAGEN – Geographic focus
Exhibit 72: QIAGEN – Segment focus
Exhibit 73: QIAGEN – Key offerings
Exhibit 74: Validation techniques employed for market sizing



【掲載企業】

Abbott Laboratories、BD、F. Hoffmann-La Roche、Hologic、QIAGEN

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[子宮頸癌診断検査の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆